Oura, the Finnish-American company that turned a titanium ring into one of the most talked-about health-tracking devices on the market, filed paperwork on September 21, 2026 to go public on the Nasdaq under the ticker symbol OURA. The filing lifts the curtain on a business that has grown explosively, while still losing money at scale, as it tries to convince investors it is more than a fashionable fitness gadget.
The numbers behind the filing
Oura is seeking to raise as much as $2.2 billion by selling roughly 50 million shares, split between 13.5 million new shares and 36.5 million shares from existing investors and early backers cashing out, at an indicated price range of $40 to $44 a share. At the top of that range, the company would carry a fully diluted valuation of about $15.62 billion, a significant jump from the roughly $11 billion valuation it commanded in a private funding round in 2025. The company disclosed revenue of $1.21 billion for the nine months ending in June 2026, up 74% from the same period a year earlier, alongside a net loss that widened to $924.3 million over the same stretch.
Who is actually buying the ring
Oura’s filing showed the company has around 5 million paying subscribers, who pay a monthly membership fee on top of the ring’s upfront cost to unlock its full suite of sleep, recovery, and readiness scores. Notably, women make up 72% of Oura’s customer base, a demographic skew the company has leaned into with features like cycle tracking and, more recently, health tools tied to monitoring patients using GLP-1 weight-loss drugs like Ozempic and Wegovy, a category Oura is betting will keep driving new subscribers as GLP-1 use becomes more widespread.
From niche sleep tracker to health-data platform
Oura’s pitch to public investors leans heavily on a feature called Health Radar, which the company says can assess cardiovascular and respiratory signals from the ring’s sensors and flag patterns that may warrant a user’s attention, part of a broader industry push to reposition wearables as tools for catching health problems early rather than simply counting steps or sleep hours. That positioning puts Oura in more direct competition not just with fitness-band rivals but with a widening field of medical-grade wearables now racing to add clinically meaningful alerts, from heart-rhythm irregularities to blood-pressure trends, as regulators and hospital systems pay closer attention to what consumer devices claim to detect.
A widening loss investors will have to explain away
The nearly billion-dollar net loss over nine months is likely to be the central tension in Oura’s public offering: bulls will point to 74% revenue growth and a fast-expanding subscriber base as evidence the company is still in a land-grab phase where reinvestment matters more than profit, while skeptics will note that a hardware company burning close to a billion dollars while its core rival, Whoop, and tech giants like Apple, Samsung, and Google all compete for the same wrist- and finger-worn real estate faces a genuinely crowded, capital-intensive market. How public markets price that trade-off, growth now versus profit later, will shape whether the IPO is remembered as a validation of the wearable health category or a cautionary tale about hardware companies chasing subscription revenue.
Part of a bigger wearable moment
Oura’s filing lands amid a broader surge of capital and attention flowing into AI-powered wearables, as smart rings, continuous monitors, and sensor-laden watches increasingly market themselves on the strength of the algorithms interpreting their sensor data rather than the hardware itself. The IPO, if it prices as planned during the week of September 28, 2026, would stand as one of the largest public listings yet for a consumer health-wearable company, a milestone that could either open the door for competitors to follow Oura to public markets or serve as a cautionary data point if the stock struggles once its losses come under quarterly scrutiny.
What happens after the ring goes public
Assuming the IPO proceeds as filed, Oura’s first several quarters as a public company will likely center on two questions: whether revenue growth can hold up once the current wave of new subscribers matures, and whether management can chart a credible path toward narrowing its losses without slowing the growth that justified a $15.6 billion valuation in the first place. Investors, competitors, and the broader wearable-health industry will be watching closely, since Oura’s results as a public company will offer one of the clearest real-world tests yet of whether the AI-driven wearable-health boom can translate into a durable, profitable business rather than just a well-funded one.
Photo: Edmond Dantès / PEXELS via Pexels
